to the market

Local investor leads $5M funding round of sustainability-focused tech company founded by Houston native

Curate Capital has announced its latest portfolio company. Photo courtesy of Curate Capital

A Houston investor has led the latest funding round for a New York-based tech company focused on democratizing access to the global supply chain through its turn key solution for ethical manufacturing.

Curate Capital, a fund focused on early-stage, female-founded companies, led TO THE MARKET's $5 million series A round, the firms announced this week. TO THE MARKET has created a technology platform that provides makers from around the world with the opportunity of fair pay, safe work, and economic empowerment. After several years of growth, the company now represents a syndicated supply chain of over 200 makers in more than 50 countries.

"We are honored to join forces with TO THE MARKET to amplify further their work powering the ethical supply chain," says Carrie Colbert, Curate Capital founding and general partner, in a news release. "At Curate Capital, we are industry-agnostic, but rather look across industry boundaries to identify the very best companies being built by women for the benefit of other women. Making an investment in the ESG space has been a high priority for us, and no one is better suited to build a successful company in this realm than Jane Mosbacher Morris. She is uniquely suited and qualified to transform retail manufacturing."

Several other investors supported the round, including Working Capital Fund, Spouting Rock, Forward Ventures, Belle Fund, Knightsgate Ventures, and a number of angel investors.

Mosbacher Morris, who originally started her career in the state department in counterterrorism, founded the company in 2016. She's a Houston native and still has family locally.

"I am thrilled that Curate Capital is leading the round because of their deep expertise in scaling women-focused businesses," says Mosbacher Morris in the release. "Women are the majority of garment workers, the majority of buyers at retail organizations, and the majority of consumers. But typically they are not the factory owners, the company CEOs, or the investors on the cap table. It's great to be a part of changing that dynamic."

The company will use the funds to support its growth. Last year, Mosbacher Morris was named one of 2020's Heroes Of The Pandemic for TO THE MARKET's swift pivot to manufacturing PPE for healthcare workers, according to the release.

Curate Capital was founded in 2020 by Colbert and Mark Latham. The firm, and its initial $10 million fund, is focused on funding early-stage, female-founded companies. The company also recently announced an investment in Houston startup Ampersand's pre-seed round.

Colbert recently joined the Houston Innovators Podcast to discuss her fund. Listen to the episode below.


Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News